| Document |
Document Title |
|
WO/2013/180881A1 |
Disclosed are methods of purifying the compound (20R,22R)-2-metJiylene-19- nor-22-methyl-1α,25-dihydroxyvitamin D3 to obtain the compound in crystalline form. The methods typically include the steps of dissolving a product containing th...
|
|
WO/2013/154752A1 |
5-cholesten, 3β, 25-diol, disulfate (25HCDS) has been found to be an authentic PPARϒ agonist and LXR antagonist, and is used for the therapy of lipid disorders and inflammatory diseases, including without limitation fatty liver, inflam...
|
|
WO/2013/059021A1 |
This invention discloses 2-methylene- vitamin D analogs of formula ( I) (wherein R and X are as defined in claim 1 ), and specifically (20S)-25- hydroxy-2-methylene- vitamin D3 and (20R)-25-hydroxy-2-mcthylene-vitamin D3, as well as phar...
|
|
WO/2013/059060A1 |
This invention discloses 2-methylene-vitamin D analogs, and specifically (20S)- lα,25-dihydroxy-2-methylene-vitamin D3 as well as (5E)-(20S)-lα,25-dihydroxy-2- methylene-vitamin D3 and (20R)-lα,25-dihydroxy-2-methylene- vitamin D3, as...
|
|
WO/2013/032740A1 |
A method of purifying 1α-hydroxy-20-methyl-2 -methylene- 19,24,25,26, 27- pentanorvitamin D3 to obtain 1α-hydroxy-20-methyl-2-methylene- 19,24,25, 26,27- pentanorvitamin D3 in crystalline form. The method includes the steps of preparin...
|
|
WO/2013/032846A1 |
Compounds of Formula (I) are provided where R1 and R2 are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions and are useful in treating a variety of biological ...
|
|
WO/2013/023327A1 |
A new compound 1 which structure is as shown in formula 1 and its preparation method are provided. The synthesization of it is as follows: reacting (S)-2-methyl-3-hydroxy-methyl propionate as the original material with methyl metallic re...
|
|
WO/2013/012644A1 |
This invention discloses 2-methylene-20(21)-dehydro-19,24,25,26, 27-pentanor-vitamin D analogs, and specifically 2-methylene-20(21)-dehydro-19,24,25,26,27-pentanor-1α-hydro
xyvitamin D3, and pharmaceutical uses therefor. This compound e...
|
|
WO/2013/003307A1 |
This invention discloses 2-methylene-(22E)-25-hexanoyl-24-oxo-26,27-cyclo-22- dehydro-19-nor-vitamin D analogs, and specifically 2-methylene-(22E)-25-hexanoyI-24- oxo-26,27-cycIo-22-dehydro-19-nor-lα-hydroxyvitamin D3, and pharmaceutica...
|
|
WO/2012/174095A1 |
This invention discloses 3-desoxy-2-methylene-19-nor-vitamin D analogs, and specifically (20S)-3-desoxy-2-methylene-l a,25-diydroxy-19-nor-vitamin D3 and (20R)-3- desoxy-2-methylene-la,25-dihydroxy- 19-nor-vitamin D3 as well as pharmaceu...
|
|
WO/2012/166938A2 |
Cyclopropane-containing vitamin D analogs of formulas I and IV are provided. Such compounds may be used in preparing pharmaceutical compositions and are useful in treating a variety of biological conditions.
|
|
WO/2012/158794A1 |
This invention discloses N-cyclopropyl-(20R)-2 -methylene-19,26,27-trinor-25-aza-vitamin D analogs, and specifically N-cyclopropyl-(20R)-2-methylene-19,26,27-trinor-25-aza-1α-h
ydroxyvitamin D3 and pharmaceutical uses therefor. This com...
|
|
WO/2012/151420A1 |
This invention discloses 2α-methyl and 2β-methyl analogs of 19,26-dinor-1α,25-dihydroxyvitamin D3 and pharmaceutical uses therefor. These compounds exhibit in vitro biological activities evidencing use as an anti-cancer agent and for ...
|
|
WO/2012/122451A2 |
The present invention relates to Maxacalcitol polymorphs and Maxacalcitol having low residual solvent content as well as processes for their preparation. The present invention also relates to pharmaceutical compositions containing Maxaca...
|
|
WO/2012/118154A1 |
Provided is a compound that functions as a selective vitamin D receptor modulator and has effect selectivity or tissue selectivity that induces other effects, without inducing hypercalcemia. The compound indicated by formula (I), a solva...
|
|
WO/2012/065050A1 |
This invention discloses 22-haloacetoxy-homopregnacalciferol analogs and specifically 22-bromoacetoxy-homopregnacalciferol and pharmaceutical uses therefor. This compound exhibits relatively little calcemic activity and does not promote ...
|
|
WO/2012/057068A1 |
Provided is a novel vitamin D3 derivative which is useful as a therapeutic agent for osteoporosis. Specifically provided is a vitamin D3 derivative represented by formula (1) or a pharmaceutically acceptable solvate thereof. In the formu...
|
|
WO/2012/044689A1 |
A method of purifying (20R,25S)-2-methylene-l9,26-dinor-lα,25-dihydroxyvitamin D3 to obtain (20R,25S)-2-methylene-l9,26-dinor-lα,25-dihydroxyvitamin D3 in crystalline form. The method includes the steps of preparing a solvent of methan...
|
|
WO/2011/127465A2 |
The present invention relates to SHIP inhibitor compounds and methods for using these compounds. In particular, the present invention discloses the following methods: (i) a method of treating graft versus host disease in a subject; (ii) ...
|
|
WO/2011/121152A1 |
The present invention relates to two chiral compounds, to a method for the synthesis thereof and to the use thereof as precursors for obtaining analogues of Gemini vitamin D3. The vitamin D analogue known as Gemini, having two side chain...
|
|
WO/2011/120162A1 |
1 a-hydroxy vitamin D2 (doxercalciferol) of exceptionally high purity and stability is prepared by a process involving chromatographically purifying 1 α-hydroxyvitamin D2 monoacetate, chemically removing the acetate protectant group fro...
|
|
WO/2011/119610A2 |
Compounds of formula I are provided where X1, X2 and X3 are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions and are useful in treating a variety of biologica...
|
|
WO/2011/119622A1 |
Compounds of formula I are provided where X1, X2, and X3 are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions and are useful in treating a variety of biologic...
|
|
WO/2011/066506A1 |
Compounds of formula I are provided where X1 and X2 are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions and are useful in treating a variety of biological co...
|
|
WO/2011/002756A2 |
An air-stable, high-melt 1a-hydroxy-vitamin D3 compound, methods for preparing an animal feed composition, methods of preparing 1α-hydroxy-vitamin D3,methods of enhancing phytate phosphorus and calcium utilization, and an animal feed re...
|
|
WO/2010/120698A1 |
Disclosed is a compound of Formula (I), in which R1, R2, R3, R4, R5, R6, X, and a are defined herein, or a pharmaceutically acceptable salt thereof. Also disclosed are a pharmaceutical composition comprising a compound or salt therof of ...
|
|
WO/2010/095425A1 |
Provided is a method for producing crystals of a vitamin D derivative represented by formula (I), with which the production can be performed economically in a shorter time than the conventional methods. A crude material of the vitamin D ...
|
|
WO/2010/060197A1 |
Processes for preparing vitamin D2 derivatives and intermediates to vitamin D2 derivatives are disclosed. An improved photolysis process for the preparation of cis intermediate (I) from the trans starting material (II) are disclosed. Als...
|
|
WO/2010/009879A2 |
The present invention is directed to novel processes for the preparation of paricalcitol to novel intermediates used in these processes, and to processes for preparation of the novel intermediates.
|
|
WO/2010/011906A1 |
A composition for oral or parenterally administration comprising a single dose of 25-hydroxy-vitamin D3 sufficient to elevate the serum level in a human to a concentration in the range of 30 ng/ml to 200 ng/ml for at least 7 days and a p...
|
|
WO/2010/006125A2 |
This invention discloses 2-methylene-19,26-dinor-(20R,22E,25R)-vitamin D analogs, and specifically 2-methylene-19,26-dinor-(20R,22E,25R)-1α,25- dihydroxyvitamin D3, and pharmaceutical uses therefor. This compound exhibits transcription ...
|
|
WO/2010/006172A2 |
This invention discloses 2-methylene-20(21)-dehydro-19-nor-vitamin D analogs, and specifically 2-methylene-20(21)-dehydro-19-nor-1α,25-dihydroxyvitamin D3, and pharmaceutical uses therefor. This compound exhibits relatively high transcr...
|
|
WO/2010/006129A2 |
This invention discloses 2-methylene-(22E)-25-(l-methylene-hexyl)-26,27- cyclo-22-dehydro-19-nor-vitamin D analogs, and specifically 2-methylene-(22E)-25- ( 1 -methylene-hexyl)-26,27-cyclo-22-dehydro- 19-nor- 1 α,24(R)-dihydroxyvitamin ...
|
|
WO/2010/006162A2 |
This invention discloses 2-methylene-(20E)-20(22)-dehydro-19-nor-vitamin D analogs, and specifically 2-methylene-(20E)-20(22)-dehydro-19-nor-lα,25- dihydroxyvitamin D3, and pharmaceutical uses therefor. This compound exhibits relatively...
|
|
WO/2010/006135A2 |
This invention discloses 2-methylene-(17Z)-17(20)-dehydro-19,21 -dinor-vitamin D analogs, and specifically 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-1α,25-dihydrox
yvitamin D3, and pharmaceutical uses therefor. This compound exhibits...
|
|
WO/2010/006169A2 |
This invention discloses 2-methylene-19,26-dinor-(20S,22E,25R)- vitamin D analogs, and specifically 2-methylene-19,26-dinor-(20S,22E,25R)-lα,25- dihydroxyvitamin D3, and pharmaceutical uses therefor. This compound exhibits transcription...
|
|
WO/2009/117831A9 |
Hybrid molecules comprising a vitamin D receptor agonist moiety and an HDAC inhibitor moiety are described herein. The HDAC inhibitor moiety can be derived from an HDAC inhibitor comprising a functionality selected from the group consist...
|
|
WO/2009/111873A1 |
A stabilized 1,25 -dihydroxy vitamin D2 composition, free of methyl formate, which is particularly well suited for pharmaceutical formulations, pharmaceutical formulations of the 1,25 -dihydroxyvitamin D2 composition, and a method of mak...
|
|
WO/2009/094426A1 |
13,13-Dimethyl-flfes-C,D analogs of lα,25-dihydroxy-19-nor-vitamin D3 compounds and topical composition dosage forms thereof, and methods of treating skin conditions thereof. Exemplary active pharmaceutical ingredients include (lR,3R)-5...
|
|
WO/2009/086439A2 |
This invention discloses 2-methylene-(20S,25S)-19,26-dinor-vitamin D analogs, and specifically 2-methylene-(20S,25S)-19,26-dinor-lα,25- dihydroxyvitamin D3, and pharmaceutical uses therefor. This compound exhibits pronounced activity in...
|
|
WO/2009/086437A1 |
This invention discloses (20R)-23,23-difluoro-2-methylene-19-nor-bishomopregnacalcife
rol-vitamin D analogs, and specifically (20R)-23,23-difluoro-lα-hydroxy-2-methylene-19-nor-bishomop
regnacalciferol, and pharmaceutical uses therefor....
|
|
WO/2009/086440A1 |
This invention discloses 2-methylene-20-methyl-19,24,25,26,27-pentanor- vitamin D analogs, and specifically 2-methylene-20-methyl-lα-hydroxy-19,24,25,26,27-pentanor- vitamin D3, and pharmaceutical uses therefore. This compound exhibits ...
|
|
WO/2009/086436A1 |
This invention discloses (20S)-23,23-difIuoro-2-methylene-19-nor-bishomopregnacalcife
rol-vitamin D analogs, and specifically (20S)-23,23-difluoro- 1 α- hydroxy-2-methylene-19-nor-bishomopregnacalciferol, and pharmaceutical uses therefo...
|
|
WO/2009/067578A2 |
The invention relates to compounds that are vitamin D receptor activators, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained durin...
|
|
WO/2009/022041A1 |
The invention relates to an ointment for treating and healing human skin diseases, such as psoriasis, dermatitis, acne, herpes and fungal diseases, consisting of a composition obtained from ingredients such as petroleum jelly, clobetasol...
|
|
WO/2009/008754A2 |
Process comprising the step of reacting a C-22 phenylsulphonyl derivative of cholecalciferol of Formula (2), wherein R1 and R2 are the same or different and represent hydroxyl protecting groups, with a silyl derivative of alfa-hydroxy al...
|
|
WO/2008/128782A2 |
The invention is directed to a photochemical process for the preparation of a previtamin D or a derivative thereof from a 7-dehydrosterol or a corresponding derivative thereof which process comprises irradiating the 7-dehydrosterol or th...
|
|
WO/2008/128783A2 |
The invention is directed to a photochemical process for the preparation of a previtamin D or a derivative thereof from a 7-dehydrosterol or a corresponding derivative thereof which process comprises irradiating the 7-dehydrosterol or th...
|
|
WO/2008/131267A2 |
The disclosure provides compounds, compositions and methods using these compounds and compositions to stimulate the differentiation of cells and inhibit excessive cell proliferation of certain cells, including cancer cells and skin cells...
|
|
WO/2008/125901A2 |
Compounds of formula I are provided where X1, X2 and X3 are independently selected from H or hydroxy protecting groups. Such compounds are used in preparing pharmaceutical compositions and are useful in treating a variety of biological c...
|
